Cobra Biomanufacturing signs agreement with Debiopharm to supply biopharmaceutical protein

Cobra Biomanufacturing Plc. (AIM: CBF), today announces an agreement with Debiopharm S.A., a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNFá Kinoid.

The agreement includes process development and supply of material for clinical trials. The new agreement replaces a prior manufacturing deal with Neovacs SA, who has licensed the programme to Debiopharm.

David Thatcher, CEO of Cobra, said: “We are pleased to continue with the process development aspect of the TNFá kinoid project whilst forging a new relationship with Debiopharm. This agreement recognises Cobra’s previous success in this project and our expertise in producing therapeutic protein vaccines.”